Connect with us

Life Sciences

BioSkryb Genomics to Bring High-Throughput Automation to Single-Cell Genomics

The product solution combines HP’s new D100 Single Cell Dispenser with BioSkryb’s ResolveDNA® technology to enable the investigation of large single-cell…

Published

on

This article was originally published by AITHORITY
BioSkryb Genomics to Bring High-Throughput Automation to Single-Cell Genomics

The product solution combines HP’s new D100 Single Cell Dispenser with BioSkryb’s ResolveDNA® technology to enable the investigation of large single-cell genomics studies with unprecedented coverage and accuracy

BioSkryb Genomics, a pioneer in comprehensive single-cell multiomic research solutions, optimized a high-throughput workflow of BioSkryb’s ResolveDNA Single-Cell Whole Genome Amplification technology on HP’s new D100 Single Cell Dispenser to deliver single-cell genomics at scale.

AiThority Interview Insights: How to Get Started with Prompt Engineering in Generative AI Projects

“This will generate single-cell genomic and multiomic data on an unprecedented scale, opening the door to a new realm of exploration possibilities across oncology, cell and gene therapy, neurology, reproductive genomics, microbiome, and other important applications of genomics.”

BioSkryb’s ResolveDNA whole genome amplification technology unlocks the ability for users to accurately examine whole genomes from single cells and reveals novel insights on the molecular drivers of disease. HP’s D100 Single Cell Dispenser makes accessible single-cell analysis with high occupancy, viability, and precision. HP’s simple but powerful software combines cell isolation and reagent dispense for workflow miniaturization.

“The ability to read out the entire genome of individual cells at high resolution will transform our efforts to understand cancer development,” said Dr. Alexander Bick, M.D. Ph.D. from Vanderbilt University Medical Center’s Division of Genetic Medicine. “The combination of BioSkryb’s high throughput ResolveDNA solution with the HP D100 Single Cell Dispenser has enabled us to increase our single cell whole genome sequencing throughput by a factor of 50.”

Read More about AiThority InterviewAiThority Interview with Frank Diana, Principal Futurist at Tata Consultancy Services

By merging these powerful technologies, investigators will now be able examine whole genomes of large sample cohorts like never before. With this level of throughput, BioSkryb’s technology can be easily and accurately applied in large sample projects analyzing tens of thousands of cells.

“Through the combination of ResolveDNA and D100 Dispenser, our customers will be able to apply true single-cell genomic and multiomic analysis to projects with sample sizes in the thousands, and reduce the cost of these large projects,” said Suresh Pisharody, CEO of BioSkryb Genomics. “This will generate single-cell genomic and multiomic data on an unprecedented scale, opening the door to a new realm of exploration possibilities across oncology, cell and gene therapy, neurology, reproductive genomics, microbiome, and other important applications of genomics.”

In initial testing that analyzed thousands of single cells, deployment of the BioSkryb ResolveDNA chemistry with the HP D100 created high uniformity of single-cell genomic amplification. High DNA yield was observed across the sample set, with high allelic balance and genomic coverage as seen in downstream whole-genome sequencing.

 Latest AiThority Interview Insights : AiThority Interview: Top AI and ML Trends Transforming the Customer Service Industry

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post BioSkryb Genomics to Bring High-Throughput Automation to Single-Cell Genomics appeared first on AiThority.


gene therapy
microbiome



medicine

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending